Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4249 - A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer


09 Oct 2016


Poster display


Ricardo Fernandes


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


R. Fernandes1, S. Mazzarello2, M.F. Ibrahim3, J. Hilton3, A. Joy4, M. Ong3, B. Hutton5, L. Vandermeer6, M. Clemons3

Author affiliations

  • 1 Department Of Medicine, Division Of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, K1H 8L6 - Ottawa/CA
  • 2 Ottawa Hospital Research Institute, University of Ottawa Faculty of Medicine, K1H 8L6 - Ottawa/CA
  • 3 Department Of Medicine, Division Of Medical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa/CA
  • 4 Department Of Oncology, Division Of Medical Oncology, University of Alberta Cross Cancer Institute, Edmonton/CA
  • 5 Department Of Epidemiology And Community Medicine, University of Ottawa Faculty of Medicine, Ottawa/CA
  • 6 Ottawa Hospital Research Institute, University of Ottawa Faculty of Medicine, Ottawa/CA


Abstract 4249


Taxane acute pain syndrome (TAPS) is characterized by myalgia and arthralgia starting 24-48 hours after taxane-based chemotherapy and lasting up to 7 days. Despite its negative impact on patient quality of life, its characteristics and natural history remain poorly defined. This study evaluates persistence, severity and the impact of TAPS on quality of life (QoL).


Eligible patients with breast or prostate cancers commencing taxane-based chemotherapy completed the Functional Assessment of Cancer Therapy-Taxane (FACT-T), Brief Pain Inventory (BPI) questionnaires and a pain medication diary daily for 1 week after each chemotherapy infusion. TAPS was defined through myalgias and arthralgias on questionnaires.


From March to December 2015, of 52 patients enrolled 25 completed the study. 66% of breast patients reported TAPS. TAPS started 24-72 (range 24-96) hours after treatment infusion reaching a peak by day 3 (range 1-5). TAPS was more common in the legs and back. Dose reductions, delays or treatment discontinuation were not required due to TAPS. Medications used to treat TAPS included opioids (n = 5) and NSAIDs (n = 9). There was negative effect of pain on QoL in pain scores at baseline in comparison with the final infusion cycle (mean change in “BPI worst pain” score was +1.61 and FACT-T score was -6.9, with p-values 0.014 and 0.017, respectively).

TAPS characteristics

TC (n = 10) FEC-D (n = 2) Single agent Palcitaxel(N = 9) AC-P or AC-D (n = 3)
TAPS Incidence 80% 50% 22% 100%
Growth factor use (n) 7 1 0 1
Taxane Dosing at 100 mg/m2 No Yes No Yes
Oral Steroids use (n) 8 1 0 2

TC - cyclophosphamide plus docetaxel; FEC-D - 5-fluorouracil-epirrubicin-cyclophosphamide followed by docetaxel; AC-D - doxorubicin-cyclophosphamide followed by docetaxel; AC-T - doxorubicin-cyclophosphamide followed by paclitaxel


TAPS is a common toxicity and associated with a negative impact on QoL. Further data will help define predisposing risk factors. Prospective patient reported outcome assessments are crucial to individualize treatment strategies and to improve management of TAPS.

Clinical trial identification


Legal entity responsible for the study

Ottawa Hospital Regional Cancer Centre


Ottawa Hospital Regional Cancer Centre (Internal)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings